Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 13/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 13/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236713 | 0.88 | MCHR1 (0.41) | TAS1R3TAS1R1PDE4DPDE4APDE4B | |
| SCHEMBL4689270 | 0.88 | BCL9 (0.45) | BCL9CTNNB1PDE4DPDE4APDE4B | |
| SCHEMBL4233744 | 0.88 | MAPT (0.39) | TAS1R3TAS1R1PDE4DPDE4APDE4B | |
| SCHEMBL4236270 | 0.87 | MCHR1 (0.39) | TAS1R3TAS1R1LMNAMAPT | |
| SCHEMBL4232148 | 0.87 | MCHR1 (0.40) | TAS1R3TAS1R1PDE4DPDE4APDE4B | |
| SCHEMBL4242203 | 0.87 | ACKR3 (0.42) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL4235502 | 0.85 | TAS1R3 (0.40) | BCL9CTNNB1TAS1R3TAS1R1PKM | |
| SCHEMBL4683749 | 0.85 | LMNA (0.39) | TAS1R3TAS1R1LMNAMAPT | |
| SCHEMBL4237351 | 0.84 | LMNA (0.39) | TAS1R3TAS1R1LMNAMAPT | |
| SCHEMBL4687977 | 0.83 | PKM (0.43) | BCL9CTNNB1TAS1R3TAS1R1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | BCL9 3638/4885CTNNB1 4509/4885TAS1R3 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.